Advanced search
Publication Cover
Postgraduate Medicine Volume 125, 2013 - Issue 3
Submit an article Journal homepage
108
Views
8
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes and Concomitant Disorders

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials

William Cook Medical Affairs, AstraZeneca, Wilmington, DECorrespondence[email protected]
, PhD,
Brian Bryzinski Research and Development, AstraZeneca, Wilmington, DE
, MD,
Jill Slater Clinical Development, Bristol-Myers Squibb, Princeton, NJ
, PharmD,
Robert Frederich Clinical Development, Bristol-Myers Squibb, Princeton, NJ
, MD &
Elsie Allen Medical Affairs, Bristol-Myers Squibb, Princeton, NJ
, MD
Pages 145-154 | Published online: 13 Mar 2015

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Simona Cernea, Avivit Cahn & Itamar Raz. (2016) Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety 15:5, pages 697-707.
Read now
Peter P Toth. (2015) Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vascular Health and Risk Management 11, pages 9-23.
Read now
Gina Ryan. (2015) Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. Postgraduate Medicine 127:8, pages 842-854.
Read now
George S Panagoulias & John Doupis. (2014) Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. Patient Preference and Adherence 8, pages 227-236.
Read now
William Cook, Gianmaria Minervini, Brian Bryzinski & Boaz Hirshberg. (2014) Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials. Postgraduate Medicine 126:6, pages 19-32.
Read now

Articles from other publishers (3)

E. Bonora, B. Bryzinski, B. Hirshberg & W. Cook. (2016) A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. Nutrition, Metabolism and Cardiovascular Diseases 26:5, pages 374-379.
Crossref
Rajeev Jain. (2015) Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. Advances in Therapy 32:11, pages 1065-1084.
Crossref
Katherine A. Lyseng-Williamson & Lily P. H. Yang. (2014) Saxagliptin: a guide to its use in type 2 diabetes mellitus. Drugs & Therapy Perspectives 30:3, pages 92-99.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.